news
European Commission extends approval of cystic fibrosis medicine
For the first time, a medicine to treat the most common form of cystic fibrosis has been approved in paediatric patients aged one to under two years old.
List view / Grid view
Orkambi (lumacaftor/ivacaftor)
news
NHS England and Vertex announce agreement for cystic fibrosis medicines
A new agreement will allow eligible cystic fibrosis patients in England to have access to CFTR modulators to treat the underlying cause of their disease.
news
Pricing dispute over cystic fibrosis drug Orkambi continues in the UK
Campaigners call for UK Government to intervene on pricing dispute over cystic fibrosis drug Orkambi...
news
Vertex in long-term reimbursement agreement with ROI for CF medicines
Vertex Pharmaceuticals has reached an agreement with ROI to fund Orkambi for all of the approximately 500 people in Ireland with cystic fibrosis...
news
SMC says ‘no’ to Kalydeco and Orkambi in cystic fibrosis
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.
news
NICE says ‘no’ to cystic fibrosis drug Orkambi in draft guidance
The National Institute for Health and Care Excellence (NICE) has issued draft guidance which does not recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis.
